



# **Circulating Tumor Cell (CTC) Diagnostics:** *Technologies and Global Markets*

May 2018

*Usha Nagavarapu*



Report Code: PHM153B

# Table of Contents

<b>Chapter 1: Introduction</b> .....	<b>1</b>
Study Goals and Objectives.....	1
Reasons for Doing This Study.....	1
Intended Audience.....	2
Scope of the Study .....	2
Methodology.....	2
Information Sources.....	3
Geographic Breakdown.....	3
Analyst's Credentials.....	6
Related BCC Research Reports.....	6
<b>Chapter 2: Summary and Highlights</b> .....	<b>8</b>
<b>Chapter 3: Circulating Tumor Cells</b> .....	<b>12</b>
Cancer .....	12
Recent Advances in Technology.....	13
Invasive Power .....	14
Circulating Tumor Cells .....	14
Phenotypic Characteristics .....	15
CTC Clusters.....	16
CTC Detection .....	16
Cancer Stem Cells (CSCs).....	17
Circulating Tumor Cells – Potential Uses.....	19
Proliferative Activity .....	23
Epithelial Marker Genes on Circulating Tumor Cells.....	24
Circulating Tumor Cells and Stem Cell-Like Phenotype .....	27
CTCs and Primary Tumor Cells: Comparison .....	27
Metastasis .....	27
Future Directions.....	28
Metastatic Development in Cancer Patients .....	30
Circulating Tumor Cell Migration .....	30
Important Markers of Distant Metastasis .....	30
Circulating Tumor Cell Detection .....	30
Methods.....	33
CellSearch Method .....	33
Epic Sciences Method.....	33
Maintrac .....	34
ISET Test .....	34
Challenges for Detection .....	35
Clinical Application of Circulating Tumor DNA.....	35
Circulating Tumor Cells as Predictor of Response to Therapy .....	36
Measurement of CTCs – Applications .....	37
Conclusion .....	37
<b>Chapter 4: Incidence of Cancer</b> .....	<b>40</b>
Worldwide Growth in the Incidence of Cancer .....	40
Causes of Cancer .....	42
Risk Factors for Cancers .....	42

Burden of Cancer.....	42
Avoiding Risk Factors.....	43
Early Detection .....	43
Treatment.....	44
Palliative Care .....	44
World Health Organization Response .....	45
World Cancer Statistics .....	45
Cancer and the Global Impact .....	49
Global Patterns.....	50
Future of Cancer.....	51
Common Types of Cancers.....	53
U.S. Cancer Incidence .....	55
Global Breast Cancer .....	57
Colorectal Cancer .....	61
Prostate Cancer .....	67
Cancer in Europe .....	88
Prostate Cancer in Asia.....	94
Other Nations .....	95
Conclusions.....	98
<b>Chapter 5: Technologies .....</b>	<b>100</b>
Finding Circulating Tumor Cells .....	100
Why CTCs?.....	100
Current CTC Detection and Isolation Methods .....	101
New Technologies for Detection.....	101
Cancer Prognosis .....	102
CTC Detection Techniques – Requirements .....	104
Nucleic Acid-based Methods.....	117
Clinical Testing.....	120
Summary .....	122
New Emerging Technologies .....	125
<b>Chapter 6: Circulating Tumor Cells and Cancer Diagnostics .....</b>	<b>130</b>
Use of CTCs for Diagnosis.....	133
Current Methods and Applications .....	140
Circulating Tumor Cells in Prostate Cancer: Case Studies.....	143
CTCs in Companion Diagnostics .....	143
Newer Technologies in Development .....	149
Molecular Analyses of CTC .....	154
Conclusions.....	155
<b>Chapter 7: CTCs in Clinical Trials .....</b>	<b>157</b>
CTC Diagnostics .....	157
Circulating Tumor Cell Technology.....	158
Potential Therapeutic Uses of Circulating Tumor Cells .....	158
Challenges in the Detection of Circulating Tumor Cells .....	159
CTCs as Clinical Biomarkers .....	160
PCR-based Markers .....	161
Circulating Tumor Cells in Cancer – Current Status .....	162
Prognostic and Predictive Value of CTCs.....	166
CTCs in Clinical Cancer Management .....	168

Existing Technologies in Clinical Trials .....	169
Clinical Studies Using CellSearch Technology.....	171
Approvals.....	173
Recent Studies.....	173
Possible Use of CTCs and DTCs as New Biomarkers.....	177
Clinical Applications.....	177
Application of CTC Technologies to Clinical Testing.....	180
CTC Technologies for Clinical Development.....	181
Standard Recommendations.....	184
CTC Number as a Prognostic Biomarker .....	187
Prognostic Studies.....	189
CTCs as a Surrogate Response Biomarker.....	189
CTCs as a Real-time Biopsy.....	190
CTC Chip Technology and EGFR Mutation Analysis.....	190
CTC Characterization after Enrichment Using the CellSearch Platform.....	191
Final Remarks .....	191
<b>Chapter 8: Circulating Tumor Cell Market.....</b>	<b>194</b>
Invasive Cancer .....	194
Cancer Survival .....	195
Global Annual Oncology Market .....	199
Cancer Therapy.....	200
Aging and Cancer.....	203
Cancer Drug Pipeline .....	203
Cancer Costs in the U.S.....	209
Japan Oncology Drugs Market .....	211
Breast Cancer .....	212
Colon and Rectum .....	214
Prostate .....	215
Chemotherapy Market.....	216
Cancer Testing Market .....	216
Current Cancer Diagnostic Tests .....	220
A Universal Tumor Test – Is it Possible?.....	221
Cancer Biomarker Testing Market.....	222
Molecular Diagnostics .....	224
Cancer Biomarker Tests.....	225
Cancer Disease Management.....	226
Personalized Cancer Testing.....	226
Circulating Tumor Cell Market – A New Approach .....	227
Clinical Diagnostics Market .....	229
Current Status of the Market .....	234
Future and Next Steps.....	249
<b>Chapter 9: Patents Overview .....</b>	<b>253</b>
Key Patents .....	254
Menarini-Silicon Biosystems/Veridex .....	255
Magsweeper.....	256
Scripps Research Institute (EPIC Sciences).....	256
CellPoint Diagnostics .....	256
University of Washington.....	256
Biofluidica.....	256

Adnagen .....	257
Filtini .....	257
Ikonisys .....	257
Aviva Biosciences.....	258
Harvard University – Mehmet Toner, PhD .....	258
Collective Dx .....	258
Johns Hopkins University .....	259
Medical Discovery Partners.....	259
Cynvenio Biosystems.....	259
ScreenCell.....	259
Canopus Bioscience.....	260
Advanced Cell Diagnostics.....	260
Biocept.....	260
Truecells .....	261
Roche Molecular Systems and the University of North Carolina .....	261
Collectar Biosciences .....	262
The General Hospital Corp. ....	262
The Trustees of the University of Pennsylvania Patents .....	262
Epic Sciences.....	263
Immunomedics.....	263
<b>Chapter 10: Selected Company Profiles .....</b>	<b>265</b>
Companies .....	265
Key Players .....	265
Key Company Profiles .....	266
<b>About BCC Research.....</b>	<b>279</b>
About BCC Research.....	280
BCC Membership .....	280
BCC Custom Research .....	280

# List of Tables

Summary Table: Global Circulating Tumor Cell Technology Market, by Cancer Type, Through 2022 (\$ Millions) .....	9
Table 1 Categories of Stem Cells.....	18
Table 2 Product Categories.....	19
Table 3 Key Success Factors of CTCs.....	20
Table 4 Types of CTCs.....	22
Table 5 Circulating Tumor Cells – Features.....	23
Table 6 Metastatic Cascade .....	29
Table 7 EPCAM-based Assays .....	32
Table 8 CellSearch Tests.....	36
Table 9 Liquid Biopsy Technologies .....	38
Table 10 Cancer – Key Facts.....	41
Table 11 Cancer Causes .....	42
Table 12 Cancer Causing Factors .....	43
Table 13 Cancer Screening Methods .....	44
Table 14 Noncommunicable Diseases Action Plan .....	45
Table 15 Global Cancer Incidence and Mortality, 2012 and 2035 (Millions).....	46
Table 16 Cancer in 2013.....	47
Table 17 Global Cancer Statistics for the Most Common Cancers, 2012 .....	48
Table 18 Increase in Cancer Burden – Factors.....	52
Table 19 Main Types of Cancers and Associated Mortality .....	54
Table 20 General Global Cancer Incidence, by Type.....	54
Table 21 Common Types of Cancers in U.S., Estimated New Cases, 2013 .....	56
Table 22 Global Breast Cancer Incidence, 2012-2022 .....	58
Table 23 Global Breast Cancer Facts.....	58
Table 24 Breast Cancer in the U.S.....	59
Table 25 Breast Cancer in U.S., 2012-2022.....	60
Table 26 Global Colorectal Cancer, 2012-2022.....	61
Table 27 Global Colorectal Cancer Incidence (Estimated): Mortality and Prevalence, 2012 (Thousands) .....	62
Table 28 Colorectal Cancer Incidence Estimates in U.S., 2012-2022.....	65
Table 29 Number of People Living with Colorectal Cancer Estimates in U.S., 2016.....	66
Table 30 Colon and Rectal Cancer Incidence Estimates in U.S., 2013-2022 .....	66
Table 31 Incidence and Deaths for Prostate Cancer, 2013 (Thousands).....	67
Table 32 Prostate Cancer Incidence and Mortality Worldwide, 2012 (Thousands) .....	72
Table 33 Highest Incidence of Prostate Cancer, by Country, 2012.....	74
Table 34 Global Estimated Prostate Cancer Deaths: Age-Standardized Mortality Rates per 100,000 Men, 2012 .....	76
Table 35 Global Estimated New Cases of Prostate Cancer, 2012-2022.....	78
Table 36 Prostate Cancer Statistics, 2016.....	80
Table 37 Estimated New Cases and Deaths of Prostate Cancer in U.S., 2012–2016 (Number) .....	81
Table 38 Estimated Prostate Cancer Cases in U.S., 2020 and 2030 (Number) .....	82
Table 39 Prostate Cancer Statistics: New Cases and Deaths in U.S., by Race, 2007-2012 .....	83
Table 40 Prostate Cancer Stage and Survival Rate (%) .....	84
Table 41 Incidence Rates by Race in U.S., 2005–2009.....	84
Table 42 Mortality Rates by Race in U.S., 2005–2009 .....	85
Table 43 Relative Survival Rate for Prostate Cancer Patients (%) .....	86
Table 44 Five-year Relative Survival by Stage at the Time of Diagnosis.....	87

Table 45 Estimated Prostate Cancer in Canada, 2015 .....	88
Table 46 Estimated Prostate Cancer Mortality in EU27 Countries: Age-Standardized Mortality Rates per 100,000 Men, 2012 .....	90
Table 47 Prostate Cancer Deaths in U.K.: Rate per 100,000 People, 2014.....	93
Table 48 Estimated Prostate Cancer Diagnosed in 2016 .....	96
Table 49 Potential Applications of CTC-based Diagnostics .....	100
Table 50 Clinical Relevance of CTC.....	104
Table 51 CTC Enrichment Methods .....	105
Table 52 Techniques Used for CTC Enrichment.....	106
Table 53 Techniques Used for CTC Analysis.....	110
Table 54 Enumeration Techniques .....	112
Table 55 Functional Assays .....	117
Table 56 Circulating Tumor Cells Technologies .....	123
Table 57 Micro-Count Features: A New Technology .....	126
Table 58 CTC Assay Pre-Analytical Validation Considerations.....	131
Table 59 CTC Assay Analytical Validation Considerations .....	132
Table 60 CTC Assay Post-Analytical Validation Considerations .....	133
Table 61 Current Enrichment Assays for CTCs.....	135
Table 62 CTC Enumeration Assays .....	138
Table 63 Characterization Assays for CTCs .....	140
Table 64 Key Features of IVD CTC Tests.....	142
Table 65 Prostate Cancer Diagnosis and Role of CTCs.....	143
Table 66 Current Diagnostic Methods .....	144
Table 67 ApoStream Key Features .....	145
Table 68 Canopus Bioscience Technology – Benefits .....	146
Table 69 CellOptics’ Cancer Application .....	147
Table 70 CellOptics’ Key Features – Enrichment .....	147
Table 71 CellOptics’ Key Features – Labeling.....	148
Table 72 CellOptics’ Key Features – Detection .....	148
Table 73 ISET Test – Specifications .....	148
Table 74 CTC Technologies for Clinical Management.....	168
Table 75 CTC Technologies for Clinical Management.....	172
Table 76 CTC Assay Clinical Readiness Evaluation .....	182
Table 77 CTC Assay Analytical Validation Considerations .....	183
Table 78 CTC Qualification Studies .....	185
Table 79 Global Cancer Incidence – Estimates, 2008–2030 (Millions) .....	194
Table 80 Global Cancer Survivors, 2008 (Millions) .....	196
Table 81 Burden of Cancer in U.S., 2016 .....	197
Table 82 U.S. Cancer Survivors, 2008–2022 (Millions) .....	197
Table 83 Male Cancer Survivors (%).....	198
Table 84 Female Cancer Survivors (%).....	198
Table 85 Global Cancer Drug Companies.....	201
Table 86 Global Cancer Drug Market, Through 2022 (\$ Millions) .....	202
Table 87 Drugs Approved in 2017.....	204
Table 88 Cancer Forecast in U.S., 2020 – Key Facts.....	209
Table 89 Cancer Care Cost in U.S., 2010 and 2020 (\$ Billions) .....	211
Table 90 Global <i>In Vitro</i> Diagnostics Market, Through 2022 (\$ Millions) .....	217
Table 91 Key Players .....	219
Table 92 Significant Developments in Cancer Follow-Up .....	221
Table 93 Cancer Tests and Limitations – the Case Against Development of a Universal Test .....	221
Table 94 Global Cancer Biomarkers Market, Through 2022 (\$ Millions).....	222

Table 95 Key Players .....	223
Table 96 Global Molecular Diagnostics Market, Through 2022 (\$ Millions) .....	224
Table 97 CTCs – Differentiating Features.....	227
Table 98 Stem Cell Market Overview.....	230
Table 99 Key Companies Selling Stem Cell Research Products.....	231
Table 100 CTC Companies with Promising Products .....	233
Table 101 Clinical Use of CellSearch System.....	234
Table 102 Estimated Pricing (Dollars) .....	235
Table 103 CellSearch Kit.....	235
Table 104 Global Circulating Tumor Cell Testing Market, by Region, Through 2022 (\$ Millions) .....	237
Table 105 Global Circulating Tumor Cells for Prostate Cancer Market, by Region, Through 2022 (\$ Millions) .....	238
Table 106 Global Circulating Tumor Cells for Breast Cancer Market, by Region, Through 2022 (\$ Millions) .....	239
Table 107 Global Circulating Tumor Cells for Colorectal Cancer Market, by Region, Through 2022 (\$ Millions) .....	240
Table 108 U.S. Circulating Tumor Cells for Prostate Cancer Market, Through 2022 (\$ Millions).....	241
Table 109 U.S. Circulating Tumor Cells Market, by Cancer Type, Through 2022 (\$ Millions) .....	243
Table 110 European Circulating Tumor Cells Market, Through 2022 (\$ Millions).....	244
Table 111 European Circulating Tumor Cells Market, by Cancer Type, Through 2022 (\$ Millions) .....	245
Table 112 Rest of World Circulating Tumor Cells Market, Through 2022 (\$ Millions) .....	246
Table 113 Rest of World Circulating Tumor Cells Market, by Cancer Type, Through 2022 (\$ Millions) ..	248
Table 114 Circulating Tumor Cell Assay Characteristics .....	253
Table 115 CTC Selected Patents.....	254
Table 116 Key Patents by Aviva Biosciences.....	258
Table 117 Commercial Circulating Tumor Cell Technology Platforms.....	265



# List of Figures

Summary Figure: Global Circulating Tumor Cell Technology Market, by Cancer Type, 2012-2022 (\$ Millions) .....	10
Figure 1 Global Cancer Incidence and Mortality, 2012 and 2035 (Millions) .....	46
Figure 2 Common Types of Cancers in U.S., Estimated New Cases, 2013 .....	57
Figure 3 Colorectal Cancer Incidence Estimates in U.S., 2012-2022 .....	65
Figure 4 Colon and Rectal Cancer Incidence Estimates in U.S., 2013-2022.....	67
Figure 5 Prostate Cancer Incidence and Mortality Worldwide, 2012 (Thousands).....	73
Figure 6 Global Estimated Prostate Cancer Deaths: Age-Standardized Mortality Rates per 100,000 Men, 2012 .....	77
Figure 7 Global Estimated New Cases of Prostate Cancer, 2012–2022.....	79
Figure 8 New Cases and Deaths of Prostate Cancer in U.S., 2012–2016 (Number) .....	82
Figure 9 Estimated Prostate Cancer Cases in U.S., 2020 and 2030 (Number).....	83
Figure 10 Prostate Cancer Deaths in U.K.: Rate per 100,000 People, 2014 .....	93
Figure 11 Global Cancer Incidence – Estimates, 2008-2030 (Millions).....	195
Figure 12 Global Cancer Survivors, 2008 (Millions) .....	196
Figure 13 Global Cancer Drug Market, 2013–2022 (\$ Millions) .....	203
Figure 14 Global <i>In Vitro</i> Diagnostics Market, 2012–2022 (\$ Millions) .....	217
Figure 15 Global Cancer Biomarkers Market, 2012–2022 (\$ Millions).....	222
Figure 16 Global Molecular Diagnostics Market, 2012–2022 (\$ Millions).....	225
Figure 17 Global Circulating Tumor Cell Testing Market, by Region, 2012–2022 (\$ Millions) .....	237
Figure 18 Global Circulating Tumor Cells for Prostate Cancer Market, by Region, 2012–2022 (\$ Millions) .....	238
Figure 19 Global Circulating Tumor Cells for Breast Cancer Market, by Region, 2012–2022 (\$ Millions).....	240
Figure 20 Global Circulating Tumor Cells for Colorectal Cancer Market, by Region, 2012–2022 (\$ Millions) .....	241
Figure 21 U.S. Circulating Tumor Cells for Prostate Cancer Market, 2012–2022 (\$ Millions).....	242
Figure 22 U.S. Circulating Tumor Cells Market, by Cancer Type, 2012-2022 (\$ Millions) .....	243
Figure 23 European Circulating Tumor Cells Market, 2012–2022 (\$ Millions).....	244
Figure 24 European Circulating Tumor Cells Market, by Cancer Type, 2012-2022 (\$ Millions) .....	245
Figure 25 Rest of World Circulating Tumor Cells Market, 2012–2022 (\$ Millions) .....	247
Figure 26 Rest of World Circulating Tumor Cells Market, by Cancer Type, 2012-2022 (\$ Millions) .....	248



*About BCC Research*

## *About BCC Research*

With our unparalleled 45-year history, BCC Research provides comprehensive analyses of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

## *BCC Membership*

From market sizing and forecasts to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or E-mail [info@bccresearch.com](mailto:info@bccresearch.com) to request a demo.

## *BCC Custom Research*

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: [custom@bccresearch.com](mailto:custom@bccresearch.com) or 781/205-2429.

## DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-689-9  
May 2018